Coronary Artery Disease: The Complete Guide to Diagnosis, CABG, and PCI.

Coronary artery disease (CAD) is the progressive narrowing and hardening of the coronary arteries — the blood vessels that supply oxygen-rich blood to the heart muscle itself. It remains the leading cause of death worldwide, responsible for approximately 370,000 deaths annually in the United States alone.

The pathological process is atherosclerosis: lipid-laden plaques accumulate within the arterial wall over decades, gradually narrowing the lumen and restricting blood flow. When a plaque ruptures, the resulting thrombus can acutely occlude the artery, causing a myocardial infarction (heart attack).

CAD exists on a spectrum from subclinical disease detectable only on advanced imaging to acute ST-elevation myocardial infarction (STEMI) requiring emergent revascularization. Understanding where a patient falls on this spectrum — and the natural history of their specific pattern of disease — is fundamental to making the right treatment decision.

Major risk factors for CAD include:

• Hypertension (present in ~70% of CAD patients)
• Hyperlipidemia (elevated LDL cholesterol is the primary modifiable risk factor)
• Diabetes mellitus (doubles CAD risk; present in 30-40% of patients undergoing revascularization)
• Tobacco use (triples risk of MI; cessation reduces risk by 50% within 1 year)
• Family history of premature CAD (first-degree relative with CAD before age 55 in men, 65 in women)
• Chronic kidney disease, obesity, sedentary lifestyle, psychosocial stress

Prevention remains the most powerful intervention. Statin therapy reduces major cardiovascular events by 25-35% in appropriately selected patients. Aggressive LDL lowering (target <70 mg/dL, or <55 mg/dL per ESC guidelines) with statins, ezetimibe, and PCSK9 inhibitors has been shown to stabilize and even regress coronary plaques.

The diagnostic approach to suspected CAD has evolved substantially. Current ACC/AHA guidelines (2021 Chest Pain Guideline) emphasize a tiered approach based on pre-test probability:

Non-invasive testing:

• Coronary CT angiography (CCTA): Now the preferred first-line test for patients with stable chest pain and intermediate pre-test probability (ACC/AHA Class I). CCTA provides anatomic visualization of coronary plaques and stenoses with sensitivity exceeding 95%. The SCOT-HEART and PROMISE trials demonstrated that CCTA improves diagnostic accuracy and reduces downstream costs. Coronary artery calcium (CAC) scoring, often performed alongside CCTA, provides powerful risk stratification — a CAC score of 0 effectively rules out obstructive CAD, while scores >400 identify high-risk patients.
• Stress testing: Exercise ECG, stress echocardiography, or nuclear stress (SPECT/PET) assess functional significance — does the stenosis actually cause ischemia? The ISCHEMIA trial demonstrated that the extent of ischemia on stress testing is an important prognostic marker.
• Cardiac MRI: Stress perfusion cardiac MRI offers superior spatial resolution and no radiation. The MR-INFORM trial showed it was non-inferior to invasive FFR-guided management.

Invasive testing:

• Coronary angiography (cardiac catheterization): Remains the gold standard for defining coronary anatomy. Performed when non-invasive testing suggests significant disease, or urgently during acute coronary syndromes. Provides the anatomic data needed for revascularization planning.
• Fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR): Invasive physiological tests that measure whether a stenosis is hemodynamically significant. The FAME and FAME 2 trials established FFR-guided PCI as superior to angiography-guided PCI. A stenosis is considered significant when FFR ≤0.80 or iFR ≤0.89.
• Intravascular ultrasound (IVUS) and optical coherence tomography (OCT): Intravascular imaging provides detailed plaque characterization and guides stent sizing and deployment. IVUS-guided PCI has been associated with improved outcomes compared to angiography-guided PCI, particularly in complex lesions and left main disease.

The SYNTAX score, calculated from the coronary angiogram, quantifies the complexity of coronary artery disease. A SYNTAX score ≤22 is low complexity, 23-32 is intermediate, and ≥33 is high complexity. This score is a critical input into the CABG vs PCI decision.

Before discussing revascularization, it is essential to emphasize that optimal medical therapy (OMT) is the foundation of all CAD treatment — whether a patient is managed conservatively, undergoes PCI, or has CABG. Every CAD patient should receive guideline-directed medical therapy unless there is a specific contraindication.

Core components of OMT:

• Antiplatelet therapy: Aspirin 81 mg daily (Class I). Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) after acute coronary syndrome or stent placement. Duration of DAPT depends on clinical scenario — typically 6-12 months after drug-eluting stent placement, with shorter or longer durations based on bleeding vs ischemic risk.
• Statin therapy: High-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) is a Class I recommendation for all patients with established CAD. Target LDL <70 mg/dL (ACC/AHA) or <55 mg/dL (ESC). If not achieved with maximally tolerated statin, add ezetimibe, then consider PCSK9 inhibitor (evolocumab or alirocumab).
• Blood pressure control: Target <130/80 mmHg (ACC/AHA 2017 Hypertension Guideline). ACE inhibitors or ARBs are preferred in patients with LV dysfunction or diabetes. Beta-blockers if prior MI or reduced EF.
• Diabetes management: HbA1c <7.0% in most patients. SGLT2 inhibitors (empagliflozin, dapagliflozin) and GLP-1 receptor agonists (semaglutide, liraglutide) have demonstrated cardiovascular benefit independent of glucose control and are now preferred second-line agents.
• Lifestyle modification: Smoking cessation (most impactful single intervention), Mediterranean diet, regular aerobic exercise (150+ minutes/week), weight management, cardiac rehabilitation.

The ISCHEMIA trial (2019) — the largest trial ever conducted comparing invasive management to conservative management in stable CAD — demonstrated that in patients with moderate-to-severe ischemia and no left main disease, routine invasive strategy did not reduce major cardiovascular events compared to OMT alone over 3.2 years. This landmark result reinforced that medical therapy is not a "lesser" treatment — it is a legitimate primary strategy for many patients with stable CAD.

Coronary artery bypass grafting (CABG) is one of the most studied and validated procedures in all of medicine, with over 50 years of outcomes data. Approximately 200,000 CABG procedures are performed annually in the United States.

How CABG works: The surgeon uses healthy blood vessels (grafts or conduits) to create new pathways for blood to bypass blocked coronary arteries. The procedure is typically performed through a median sternotomy (incision through the breastbone) using cardiopulmonary bypass (heart-lung machine), though off-pump CABG (beating-heart surgery) is an established alternative at experienced centers.

Graft conduits — critical to long-term success:

• Left internal mammary artery (LIMA): The gold standard conduit. LIMA-to-LAD grafting is a Class I recommendation in all CABG guidelines. The LIMA has 95% patency at 10 years and is associated with dramatically improved long-term survival. Any CABG operation should include a LIMA-to-LAD graft unless there is a compelling reason not to (e.g., subclavian stenosis, prior radiation).
• Right internal mammary artery (RIMA): Bilateral internal mammary artery (BIMA) grafting — using both the LIMA and RIMA — provides superior long-term outcomes compared to single IMA + vein grafts. The ART trial at 10 years showed improved survival with BIMA grafting. ACC/AHA guidelines give a Class IIa recommendation for BIMA grafting in appropriate patients (age <70, non-diabetic, BMI <35).
• Radial artery: The RADIAL and RAPCO trials demonstrated that radial artery grafts have superior patency to saphenous vein grafts at 5-10 years. The radial artery is now recommended as the second conduit of choice after the LIMA (Class IIa).
• Saphenous vein grafts (SVGs): Still widely used but have inferior long-term patency — approximately 50% are occluded or significantly diseased at 10 years. The trend in modern CABG is toward total arterial revascularization to minimize the use of vein grafts.

CABG outcomes (STS National Database, 2024):

• Isolated CABG operative mortality: 1.0-2.0% (risk-adjusted)
• Stroke: 1.0-1.5%
• Median hospital stay: 5-7 days
• Return to work: 6-12 weeks
• 10-year survival: 75-85% (depending on age and comorbidities)

The quality of CABG is highly surgeon-dependent. Volume-outcome data consistently shows that surgeons performing fewer than 50 annual CABG operations have measurably higher mortality rates. At high-volume centers with experienced surgeons using arterial grafting strategies, outcomes are substantially better than the national average.

Percutaneous coronary intervention (PCI) — commonly called "stenting" — is a catheter-based procedure where a balloon is used to open a blocked coronary artery, and a stent (metallic scaffold) is deployed to hold it open. PCI is performed by interventional cardiologists in the catheterization laboratory, typically with conscious sedation rather than general anesthesia.

Stent technology evolution:

• Bare-metal stents (BMS): First-generation stents with 20-30% restenosis (re-narrowing) rates. Rarely used today.
• First-generation drug-eluting stents (DES): Coated with antiproliferative drugs (sirolimus, paclitaxel) to prevent restenosis. Reduced restenosis to 5-10% but required prolonged DAPT due to late stent thrombosis concerns.
• Current-generation DES: Thinner struts, biocompatible polymers, improved drug delivery. Restenosis rates below 5%. Stent thrombosis rates below 1% at 1 year. Examples: Abbott Xience (everolimus), Medtronic Resolute Onyx (zotarolimus), Boston Scientific Synergy (everolimus with bioresorbable polymer).
• Bioresorbable scaffolds (BRS): Designed to dissolve after vessel healing, restoring natural vasomotion. The Abbott Absorb BRS was withdrawn from market after the ABSORB III trial showed higher thrombosis rates. Next-generation BRS remain in development.

PCI outcomes for stable CAD:

• Procedural success: >95%
• Procedural mortality: <0.5% for elective cases
• Major complication rate: 1-2%
• Hospital stay: same-day discharge or 1 night for uncomplicated cases
• Return to work: days to 1-2 weeks
• Target lesion revascularization at 1 year: 3-5% with current-generation DES

Where PCI excels: Single-vessel disease, focal lesions, acute coronary syndromes requiring urgent revascularization, patients with prohibitive surgical risk, and as a bridge strategy in patients who are not surgical candidates.

Where PCI is limited: Chronic total occlusions (though CTO-PCI has advanced significantly), heavily calcified lesions, diffuse disease with small vessels, and most importantly — multivessel disease in diabetic patients, where CABG has demonstrated clear superiority (FREEDOM trial).

The choice between CABG and PCI is one of the most consequential decisions in cardiology. It is also one of the most well-studied, with multiple landmark randomized trials informing current guidelines.

Landmark trials:

• SYNTAX (2009): The foundational trial. 1,800 patients with left main or three-vessel disease randomized to CABG vs PCI. At 5 years, CABG was superior in three-vessel disease (particularly high SYNTAX scores ≥33) with lower rates of MACCE and repeat revascularization. For left main disease with low SYNTAX scores, PCI was non-inferior.
• FREEDOM (2012): 1,900 diabetic patients with multivessel CAD. CABG reduced all-cause mortality by 30% compared to PCI at 5 years. This trial established CABG as the clear standard for diabetic patients with multivessel disease (ACC/AHA Class I).
• EXCEL (2016/2019): Left main disease in low-to-intermediate SYNTAX scores. 5-year results showed similar composite outcomes but with a trend toward higher all-cause mortality with PCI — generating significant controversy and a public dispute between surgical and cardiology societies.
• NOBLE (2017): Left main disease. CABG was superior to PCI at 5 years, with lower rates of the composite endpoint driven by fewer non-procedural MIs and repeat revascularization.

Current ACC/AHA recommendations (2021 Coronary Revascularization Guideline):

• Left main disease, SYNTAX ≤22: CABG (Class I) or PCI (Class IIa) — both are reasonable
• Left main disease, SYNTAX 23-32: CABG preferred (Class I); PCI reasonable (Class IIb)
• Left main disease, SYNTAX ≥33: CABG recommended (Class I); PCI should be avoided
• Three-vessel disease: CABG preferred (Class I), particularly with diabetes, reduced EF, or complex anatomy
• Multivessel disease with diabetes: CABG strongly preferred (Class I) based on FREEDOM trial survival benefit
• One- or two-vessel disease without proximal LAD: PCI generally preferred for lifestyle and recovery benefits
• Proximal LAD disease: CABG with LIMA-to-LAD provides superior long-term outcomes; PCI is an alternative for selected patients

Heart Team evaluation is a Class I recommendation for patients with multivessel or left main disease. This means the guidelines explicitly state that these decisions should NOT be made by a single physician — both a cardiac surgeon and an interventional cardiologist should participate. WhiteGloveMD's dual-physician review model fulfills this guideline requirement for every patient.

Diabetic patients: Diabetes is the single most important modifier of the CABG vs PCI decision. The FREEDOM trial showed a 30% mortality reduction with CABG compared to PCI in diabetic patients with multivessel disease. The mechanism is believed to be the LIMA graft's resistance to accelerated atherosclerosis that affects both native vessels and stented segments in diabetic patients. Current guidelines give CABG a Class I recommendation over PCI in diabetic patients with multivessel disease.

Reduced ejection fraction: Patients with ischemic cardiomyopathy (EF ≤35%) represent a particularly complex population. The STICH trial and its 10-year extension (STICHES) demonstrated that CABG plus OMT reduced all-cause mortality by 16% compared to OMT alone in patients with EF ≤35% and surgically amenable coronary anatomy. However, operative mortality is higher (3-5%), and patient selection is critical. Viability testing (cardiac MRI, PET) can identify patients most likely to benefit.

Prior CABG with graft failure: Managing patients with failed bypass grafts is complex. Redo CABG carries higher operative risk (mortality 3-6%) but may be the best option for patients with multiple failed grafts and appropriate targets. PCI to native vessels (not grafts) is often preferred when feasible. PCI to degenerated vein grafts carries embolic risk but can be effective with distal protection devices.

Chronic total occlusions (CTOs): Complete coronary artery blockages were historically considered a surgical indication. However, CTO-PCI has advanced dramatically with hybrid algorithms, retrograde techniques, and specialized equipment. Success rates at experienced centers now exceed 85-90%. The DECISION-CTO and EuroCTO trials showed no mortality benefit for CTO-PCI over OMT in stable patients, but quality of life and symptom improvement can be substantial.

Hybrid revascularization: Combining minimally invasive LIMA-to-LAD grafting with PCI to non-LAD vessels offers a potential "best of both worlds" approach. The patient gets the survival benefit of LIMA-to-LAD without the morbidity of full sternotomy. Early data is promising but definitive randomized trial evidence is still forthcoming.

The CABG vs PCI decision is perhaps the single most common reason patients seek a cardiac surgery second opinion. Data from multiple registries show that 20-30% of PCI-recommended patients would have been better served by CABG, and vice versa. The reasons for this discrepancy are systemic, not nefarious:

• Specialty bias: Interventional cardiologists are trained to perform PCI and naturally tend to see PCI-amenable anatomy. Cardiac surgeons are trained to perform CABG and tend to identify surgical candidates. This is human nature, not malpractice — but it makes multidisciplinary review essential.
• SYNTAX score interpretation: The SYNTAX score is calculated from the coronary angiogram, and studies show significant inter-observer variability. Two cardiologists may calculate different SYNTAX scores from the same angiogram, leading to different treatment recommendations.
• Institutional factors: Hospitals without cardiac surgery programs may default to PCI for patients who would benefit from CABG. Transfer to a surgical center may be appropriate but is not always discussed.
• Incomplete Heart Team process: Despite guideline recommendations, Heart Team conferences do not occur at all institutions, and even where they do, the process may be perfunctory.

A WhiteGloveMD second opinion for coronary artery disease includes independent review of catheterization films by both a cardiac surgeon and an interventional cardiologist, SYNTAX score calculation, risk assessment using STS and EuroSCORE II models, and a guideline-based recommendation with specific attention to conduit strategy (arterial vs venous grafts) if CABG is recommended. Start your review today.